A

s experimental drugs continue to fail in Alzheimer’s patients, research interest has increasingly shifted to finding a way to stop the disease long before it erodes people’s cognitive abilities.

But how do you identify the right people to target?

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.